Τίτλος:
Metastatic type 1 gastric carcinoid: A real threat or just a myth?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
AIM: To describe disease characteristics and treatment modalities in a group of rare patients with metastatic gastric carcinoid type 1 (GCA1). METHODS: Information on clinical, biochemical, radiological, histopathological findings, the extent of the disease, as well as the use of different therapeutic modalities and the long-term outcome were recorded. Patients' data were assessed at presentation, and thereafter at 6 to 12 monthly intervals both clinically and biochemically, but also endoscopically and histopathologically. Patients were evaluated for the presence of specific symptoms; the presence of autoimmune disorders and the presence of other gastrointestinal malignancies in other family members were also recorded. The evaluation of response to treatment was defined using established WHO criteria. RESULTS: We studied twenty consecutive patients with a mean age of 55.1 years. The mean follow-up period was 83 mo. Twelve patients had regional lymph node metastases and 8 patients had liver metastases. The primary tumor mean diameter was 20.13 ± 10.83 mm (mean ± SD). The mean Ki-67 index was 6.8% ± 11.2%. All but one patient underwent endoscopic or surgical excision of the tumor. The disease was stable in all but 3 patients who had progressive liver disease. All patients remained alive during the follow-up period. CONCLUSION: Metastatic GCA1 carries a good overall prognosis, being related to a tumor size of ≥ 1 cm, an elevated Ki-67 index and high serum gastrin levels. © 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Συγγραφείς:
Grozinsky-Glasberg, S.
Thomas, D.
Strosberg, J.R.
Pape, U.-F.
Felder, S.
Tsolakis, A.V.
Alexandraki, K.I.
Fraenkel, M.
Saiegh, L.
Reissman, P.
Kaltsas, G.
Gross, D.J.
Περιοδικό:
World Journal of Gastroenterology
Εκδότης:
Baishideng Publishing Group Co
Λέξεις-κλειδιά:
angiopeptin; chromogranin A; cyanocobalamin; gallium 68; gastrin; indium 111; Ki 67 antigen; octreotide; peginterferon alpha; pentetreotide in 111; proton pump inhibitor; somatostatin; tetraxetan; tracer; vesicular monoamine transporter 2, adult; article; atrophic gastritis; autoimmune disease; chemical analysis; clinical article; clinical evaluation; diarrhea; dumping syndrome; endoscopy; evaluation and follow up; fatigue; female; gastrectomy Billroth II; gastrin blood level; gastrointestinal disease; gastroscopy; histopathology; human; human tissue; immunoglobulin producing cell; intestine metaplasia; liver metastasis; lymphadenopathy; male; metastatic gastric carcinoid type 1; pernicious anemia; positron emission tomography; stomach tumor; treatment response; wedge resection, Chromogranin A; Gastrin; Metastatic gastric carcinoids; Somatostatin analogues; Stomach neuroendocrine tumor, Adult; Aged; Carcinoid Tumor; Chemotherapy, Adjuvant; Disease Progression; Europe; Female; Gastrectomy; Gastric Bypass; Gastrins; Gastroscopy; Humans; Israel; Ki-67 Antigen; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Retrospective Studies; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden
DOI:
10.3748/wjg.v19.i46.8687
